Perioperative Camrelizumab Plus Chemotherapy Improves 2-Year Event-Free Survival Over Upfront Surgery in Locally Advanced Head and Neck Cancer, With More Grade 3 or Higher Adverse Events, in an Open-Label Phase 2 Trial